// App-Quantinova.ai

: Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).

Researchers

Presenter

  • Axel Heidenreich

Principal Investigators

  • Silke Gillessen

  • Daniel Heinrich

  • Daniel Keizman

  • Joe M. O'Sullivan

  • Joan Carles

  • Manfred Wirth

  • Kurt Miller

  • Liping Huang

  • Monica Seger

  • Sten Nilsson

  • Fred Saad

Medical Centers

  • Cologne University, Cologne, Germany

  • Kantonsspital St Gallen, St Gallen, Switzerland

  • Akershus University Hospital, Lorenskog, Norway

  • Meir Medical Center, Kfar-Saba, Israel

  • The Centre for Cancer Research and Cell Biology, Queen's University Belfast and the Northern Ireland Cancer Centre, Belfast, Northern Ireland

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • University Hospital Carl Gustav Carus, Dresden, Germany

  • Charite-University Medicine Berlin, Berlin, Germany

  • Pharmaceuticals Division of Bayer, Whippany, NJ

  • Karolinska University Hospital, Stockholm, Sweden

  • University of Montreal, Montreal, QC, Canada

Locations

  • Germany

  • Switzerland

  • Norway

  • Israel

  • Spain

  • United States

  • Sweden

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Radium-223 Dichloride

  • Epimorph

Outcome

  • N/A

Study Design

  • Single Arm

  • Multinational

  • Prospective

Phase

  • NA

Study Id's

  • NCT01618370

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved